Bassil Dahiyat's recent sale of Xencor shares is the largest insider sale in the past year. It's discouraging when insiders sell below the current price, suggesting satisfaction with a lower valuation. Despite insider ownership, caution is advised due to sales history.
Xencor's share price rise doesn't match its P/S ratio, likely due to weaker forecast growth than the industry. These conditions may continue to limit the share price.
Xencor's lack of profitability and uninspiring revenue growth, despite its pursuit of growth, may have led to its share price decline. Investors may question its long-term viability with continued weak revenue growth and unprofitability.
The consistent insider selling at Xencor could be a potential red flag, although it's worth noting that no insider trades have occurred recently. The company's relatively low insider ownership does not give much reassurance.
Forecast changes hint at sales dwindling, with an expected revenue drop of 31% by end of 2024, a steep fall from 14% growth over the past five years. Xencor will likely trail in revenue growth compared to industry peers. These major downgrades might lead to a loss of market confidence in the company.
FibroGen Upgraded to Outperform at William Blair on Pamrevlumab's Potential William Blair analyst Andy Hsieh upgraded$FibroGen(FGEN.US)$to Outperform from Market Perform following a deep dive on the potential of pamrevlumab, the company's wholly owned monoclonal antibody against connective tissue growth factor, which is being evaluated in the treatment of idiopathic pulmonary fibrosis, or IPF, locally advanced pancreatic cancer, or LAP...
Xencor股票讨论区
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
William Blair analyst Andy Hsieh upgraded $FibroGen(FGEN.US)$ to Outperform from Market Perform following a deep dive on the potential of pamrevlumab, the company's wholly owned monoclonal antibody against connective tissue growth factor, which is being evaluated in the treatment of idiopathic pulmonary fibrosis, or IPF, locally advanced pancreatic cancer, or LAP...
2022前三季度营收增长18%,营业利润亏损缩小17%至0.4亿,净利润亏损扩大至0.43亿,利润主要得看第四季度业绩,目前无法判断。
暂无评论